Halozyme Therapeutics, Inc. (HALO)
NASDAQ: HALO · Real-Time Price · USD
51.28
+2.33 (4.76%)
May 16, 2025, 10:40 AM - Market open
Halozyme Therapeutics Employees
Halozyme Therapeutics had 350 employees as of December 31, 2024. The number of employees decreased by 23 or -6.17% compared to the previous year.
Employees
350
Change (1Y)
-23
Growth (1Y)
-6.17%
Revenue / Employee
$3,098,017
Profits / Employee
$1,386,751
Market Cap
6.32B
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
HALO News
- 3 days ago - Halozyme Therapeutics: Q1 Earnings Reveal A Bigger And Deeper Moat - Seeking Alpha
- 9 days ago - Halozyme Therapeutics, Inc. (HALO) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 9 days ago - HALOZYME RAISES 2025 FINANCIAL GUIDANCE RANGES AND REPORTS STRONG FIRST QUARTER 2025 RESULTS - PRNewsWire
- 10 days ago - Halozyme to Participate in the BofA Securities 2025 Healthcare Conference - PRNewsWire
- 15 days ago - Halozyme Therapeutics: Still Undervalued Ahead Of Earnings - Seeking Alpha
- 18 days ago - Halozyme to Report First Quarter 2025 Financial and Operating Results - PRNewsWire
- 18 days ago - Halozyme Announces argenx Received Positive CHMP Opinion for VYVGART® (efgartigimod alfa) Subcutaneous Injection with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - PRNewsWire
- 22 days ago - Halozyme Sues Merck for Patent Infringement over Subcutaneous Keytruda Formulation - PRNewsWire